OBJECTIVES: Determine US payer needs for health economics and outcomes research (HEOR) data for immunoglobulin G (IgG) in immune dysfunction and understand payer rationale on managing various IgG products. METHODS: We conducted a literature review of the eco­nomic burden/consequences of intravenous (IV) and subcutaneous (SC) immunoglobulin and conducted 9 US payer interviews (medical and pharmacy directors) to determine the implications of IV/SC IgG for US health plans. Interviews were conducted June 4-19, 2015, with members of RTI Health Solutions’ Payer Advisory Council. RESULTS: US payers indicated that IgG products are typically managed via prior authorization based on indication; 56% stated that failure of oral immunosuppressants and/or steroids is required prior to treatment with IgG. US payers are most concerned with the price of IgG products, followed by off-label use and administration setting costs. Eight payers considered the setting to be paramount in cost savings, stating that the inpatient setting had the highest administration fees. US payers considered the following HEOR studies to be valuable for decision making: resource utilization data, variations of care that add to costs, and head-to-head comparisons. Appropriate HEOR studies with unbiased results would be considered by stakeholders throughout US health plans. Some noted that manufacturers should conduct interviews a priori with payers to determine their thoughts and identify what economic information they would like with respect to any sponsored research. CONCLUSIONS: Payers are seeking more value-based information; emphasis needs to be on demonstrating value, comparative effectiveness, and cost offsets. Payers generally felt the cost differences in route of administration (SC vs. IV) and site may not be as evident as previously reported. Payers are uncertain of total cost of therapy differences, stating that comparisons between IV and SC need to include acquisition costs and administration fees in a transparent comparison of total therapy costs.